New York Times
by Katie Thomas
3 Jun 13
A review of a disputed clinical trial on the safety of the controversial diabetes drug Avandia did not uncover serious misconduct or fraud, according to findings by scientists at the Food and Drug Administration that were made public Monday.
But those conclusions drew sharp criticism from the F.D.A. scientist who originally sounded the alarm about the study, in an indication of how heated is the debate over the drug, inside and outside the agency.
Agency officials posted the dueling viewpoints on the F.D.A. Web site before a two-day meeting of an advisory panel, set to begin on Wednesday, that will revisit the debate over the drug. Avandia’s use was severely restricted in 2010 after several analyses, by the F.D.A. and outside researchers, found that it significantly raised the risk for heart attacks. Regulators in Europe removed it from the market.
The panel is being asked whether to widen access, retain the restrictions, modify them, or remove Avandia from the market….
http://www.nytimes.com/2013/06/04/bu...ests.html?_r=0
From 2010 –
GlaxoSmithKline deliberately hid evidence of Avandia harm, says Senate report
natural news
February 23, 2010
by Mike Adams
GlaxoSmithKline, maker of the diabetes drug Avandia, knew the drug was linked to tens of thousands of heart attacks but went out of its way to hide this information from the public, says a 334-page report just released by the Senate Finance Committee…..
Learn more: http://www.naturalnews.com/028233_Gl...#ixzz2VIMMoiaJ
....
